A reverse merger, where a private startup absorbs a listed company to inherit its exchange slot rather than run a traditional initial public offering, is how Slate Medicines is entering the public markets. The migraine drug startup, which launched earlier this year, announced Monday it will combine with Fulcrum Therapeutics, a biotech that shut its lead drug program two months ago. The combined company will trade on Nasdaq under the ticker symbol SLTE.
How Fulcrum got here
Fulcrum spent years on pociredir, a sickle cell drug designed to raise fetal hemoglobin levels by blocking a cluster of proteins called PRC2. Fetal hemoglobin is a form of the oxygen-carrying protein in blood; higher levels of it can prevent red blood cells from deforming and blocking circulation, reducing the sudden, severe pain episodes known as vaso-occlusive crises.
The path closed in two steps. The Food and Drug Administration first placed a six-month hold on Fulcrum's trial, citing concern that targeting PRC2 might raise the risk of blood cancers. Then, in June, regulators pointed to Ipsen's Tazverik, which worked through a similar mechanism, and the rate of secondary blood cancers appearing in patients on that drug. Fulcrum discontinued pociredir. Tazverik itself was pulled from the market in March. Two months after announcing it was weighing strategic alternatives, Fulcrum found a buyer.
What Slate brings to the combination
Slate raised $130 million from investors including RA Capital Management and Forbion to develop a drug that targets a protein called PACAP. Most approved migraine treatments go after a different protein, CGRP; Slate's thesis is that a PACAP inhibitor will reach patients who do not respond to those existing options. Its lead asset, codenamed SLTE-1009 and licensed from a Chinese pharmaceutical firm, is about to begin Phase 1 testing, the first stage of human trials, which measures whether a drug is safe at a given dose.
A separate $245 million financing announced alongside the merger will fund a second monoclonal antibody for migraines and a third program Slate has not yet disclosed.
The financial terms
Fulcrum held just over $333 million in cash, equivalents, and securities at the end of the first quarter of 2026. Under the deal, Fulcrum's pre-merger shareholders will receive a cash dividend equal to the amount by which that balance exceeds $20.3 million. They will keep a 5% stake in the combined company; Slate's investors will hold the remaining 95%.
Gregory Oakes, currently Slate's chief executive, will run the merged entity. The deal is expected to close by the end of 2026.